No Walk in the Park: FDA Talks Tough about Executive Accountability
This article was originally published in RPM Report
Executive Summary
If history is any guide, FDA will soon start showing its teeth as a regulatory enforcement agency. That makes this a good time for executives to refresh their memory about the doctrine of strict liability for FD&C Act violations-and to ponder the implications of the Department of Justice's recent use of the so-called Park doctrine against three top execs at Purdue Pharma.
You may also be interested in...
Sending a Message: FDA Leadership Responds to McNeil Recall
Deputy Commissioner Josh Sharfstein told a House committee investigating J&J's consumer products recall that the agency is "sending a message to industry" that it is getting tougher on manufacturing compliance. Here is his prepared testimony.
No Fault? Not Quite
An HHS departmental appeals board decision finds Purdue executives at fault despite plea and convictions based solely on the Dotterweich and Park doctrines
Bextra Settlement Coming Soon: Industry Should Brace for Impact
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety